CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 318 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05487703
NCT05487703N/ACompleted

Tofacitinib Use in Rituximab-Experienced RA Patients

Pfizer·observational·Posted Aug 4, 2022·Updated Oct 8, 2024

In Brief

An observational study for Arthritis, Rheumatoid. Completed, enrolled 318 participants across 1 site.

Detailed Summary

This study is to characterize the use of tofacitinib after use of rituximab in patients with Rheumatoid Arthritis in a real-world setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesMorocco
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedAug 4, 2022
Enrollment StartNov 14, 2022
Primary CompletionDec 23, 2022
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 3.9 years ago